Sage Therapeutics, Inc. (NASDAQ:SAGE)‘s stock had its “buy” rating reiterated by equities researchers at SunTrust Banks, Inc. in a research note issued on Wednesday. They presently have a $82.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $95.00. SunTrust Banks, Inc.’s price objective points to a potential upside of 16.53% from the company’s current price.

SAGE has been the topic of several other research reports. J P Morgan Chase & Co restated a “buy” rating on shares of Sage Therapeutics in a research report on Thursday, August 31st. Cowen and Company restated a “buy” rating and issued a $100.00 price target on shares of Sage Therapeutics in a research report on Friday, August 4th. BidaskClub lowered shares of Sage Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 23rd. HC Wainwright lifted their price target on shares of Sage Therapeutics to $86.00 and gave the stock a “neutral” rating in a research report on Friday, August 4th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $90.00 price target on shares of Sage Therapeutics in a research report on Friday, July 14th. Four analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company’s stock. Sage Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $84.08.

Sage Therapeutics (NASDAQ:SAGE) opened at 70.37 on Wednesday. The firm’s 50 day moving average price is $82.79 and its 200-day moving average price is $74.97. The stock’s market cap is $2.63 billion. Sage Therapeutics has a 52 week low of $38.30 and a 52 week high of $90.80.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by ($0.25). During the same period in the previous year, the business posted ($1.08) EPS. Analysts expect that Sage Therapeutics will post ($7.38) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Sage Therapeutics’ (SAGE) “Buy” Rating Reaffirmed at SunTrust Banks, Inc.” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/13/sage-therapeutics-inc-sage-stock-rating-reaffirmed-by-suntrust-banks-inc.html.

Several large investors have recently modified their holdings of SAGE. BlackRock Inc. boosted its stake in shares of Sage Therapeutics by 10,082.5% during the 1st quarter. BlackRock Inc. now owns 2,863,124 shares of the biopharmaceutical company’s stock valued at $203,482,000 after buying an additional 2,835,006 shares during the period. MARSHALL WACE ASIA Ltd acquired a new stake in shares of Sage Therapeutics during the 1st quarter valued at $35,493,000. Marshall Wace North America L.P. acquired a new stake in shares of Sage Therapeutics during the 1st quarter valued at $35,493,000. Point72 Asset Management L.P. boosted its stake in shares of Sage Therapeutics by 512.9% during the 1st quarter. Point72 Asset Management L.P. now owns 395,300 shares of the biopharmaceutical company’s stock valued at $28,094,000 after buying an additional 330,800 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Sage Therapeutics by 10.8% during the 1st quarter. Vanguard Group Inc. now owns 2,691,275 shares of the biopharmaceutical company’s stock valued at $191,269,000 after buying an additional 261,759 shares during the period.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.